Solid and Liquid Biopsies each offer critical insights, BUT COMBINED, they deliver a complete picture. 4baseCare’s SoLiQ combines solid and liquid biopsy methods to provide a more comprehensive genomic profile of the tumor.
This dual approach enhances the accuracy of mutation detection, facilitates real-time monitoring, and offers a fuller picture of tumor evolution, making it a powerful tool in precision oncology for adapting treatment strategies effectively.
First SoLiQ is an advanced, integrative solution that combines both Tissue (Solid Biopsy) and ctDNA (Liquid Biopsy) analysis, offering a comprehensive profiling of 72 of the most frequently mutated genes associated with solid cancers.
First SoLiQ captures complete gene sequences for key biomarkers aligned with NCCN and FDA, providing insights for targeted therapy and prognosis. It empowers clinicians to optimize care, monitor tumor evolution, and address therapeutic resistance effectively.
Indiegene SoLiQ is a comprehensive genomic profiling (CGP) test integrating tissue (solid biopsy), ctDNA (liquid biopsy), and whole blood (germline DNA) analysis. By sequencing 1,212 genes across key cancer pathways, it captures tumor and inherited variations, providing a multidimensional view of cancer genetics.
The test assesses Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) from tissue, offering insights into immunotherapy potential alongside actionable alterations in pathways like cell cycle regulation, DNA repair, and immune response. This integrative approach supports precise diagnosis, personalized therapy, and informed clinical decisions to improve patient outcomes.
Absolute SoLiQ is a cutting-edge CGP test powered by whole-exome sequencing to provide in-depth analysis of tissue (solid biopsy), ctDNA (liquid biopsy), and germline DNA from a patient’s whole blood sample. It examines approximately 20,000 genes from DNA and RNA profiling of tissue samples, 20,000 genes from germline DNA, and 1,212 genes from ctDNA. This extensive approach uncovers a broad spectrum of genetic variations, including coding mutations and regulatory elements, delivering critical insights into cancer heterogeneity and tumor biology.
A key feature of Absolute SoLiQ is its integration with Cellworks’ proprietary AI/ML algorithm, which generates the Therapy Response Index (TRI) and pathway analysis through the Cellworks Ventura™ report. This advanced computational platform translates complex genomic data into actionable therapeutic strategies, enhancing the understanding of cancer mechanisms. By aligning treatment options with each patient’s unique molecular profile, Absolute SoLiQ empowers clinicians to deliver personalized, precision-driven oncology care for optimized outcomes.
SoLiQ conducts comprehensive genomic profiling to uncover specific genomic mutations from both tissue and liquid biopsies.
Measure genomic biomarkers (prognostic, predictive and immunotherapy-related) for a more precise prognosis and treatment efficacy assessment.
SoLiQ conducts comprehensive genomic profiling to uncover specific genomic mutations from both tissue and liquid biopsies.
Measure genomic biomarkers (prognostic, predictive and immunotherapy-related) for a more precise prognosis and treatment efficacy assessment.
Consult with our specialists to learn how SoLiQ can improve precision management of cancer.
Contact us today to get started.
Kindly fill the form below to download our Liquid Biopsy Portfolio brochure :